Phase II national clinical trial of prophylactic irradiation to the contralateral breast for BRCA mutation carriers treated for early breast cancer (EBC).
Ella Evron(Sidney Kimmel Comprehensive Cancer Center), Benjamin W. Corn(Shaare Zedek Medical Center), Abraham Kuten(Rambam Health Care Campus), Diana Matceyevsky, Tami Karni(Assaf Harofeh Medical Center), Moshe Inbar(Assuta Medical Center), Bella Kaufman(NYU Langone Health), David Geffen(Ben-Gurion University of the Negev), Hadassah Goldberg(Bar-Ilan University), R. Catane(Sheba Medical Center), Merav A. Ben David(Sheba Medical Center), Ora Rosengarten(Sheba Medical Center), Roxolyana Abdah‐Bortnyak(Mansoura University), Georgeta Fried(Roche (Switzerland))
Cited by 3
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
|The Lancet|2002|1.7k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin
|New England Journal of Medicine|1997|1.6k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k